News and Events
2009
Teikoku Pharma USA Acquires Travanti Pharma Inc.
May 8, 2009
Teikoku Pharma USA Inc. announced that it has acquired Minneapolis area based Travanti Pharma Inc, a privately held corporation that designs, develops and markets innovative drug delivery platforms...
READ MORETeikoku Pharma USA and Eisai Co., Ltd Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil
March 9, 2009
Teikoku Pharma USA Inc., announces that it has signed an exclusive worldwide (excluding Japan) licensing agreement with Eisai Co., Ltd. to develop and commercialize a new transdermal formulation of donepezil, a leading compound for the treatment of Alzheimer's disease in the world.
READ MORETeikoku Enters into an Agreement with Eisai for the Development of a Transdermal Patch Formulation of Donepezil Hydrochloride
February 25, 2009
Teikoku Pharma USA and Eisai have entered into a license agreement on the donepezil patch currently being developed in all territories except Japan.
READ MORE2007
Teikoku Pharma Announces Contract with Dermatrends to Study Transdermal Application of Anti-Psychotic Drug
February 27, 2007
Teikoku Pharma USA, Inc., announced today that it has entered into an agreement with Dermatrends...
READ MOREVersatis®, Lidocaine Medicated Plaster Approved by MHRA
January 10, 2007
Teikoku Pharma annouces that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Versatis® in the UK
READ MORE